Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways
Open Access
- 4 July 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 4 (7), e702
- https://doi.org/10.1038/cddis.2013.214
Abstract
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine and a selective inducer of apoptosis in a range of tumour cells, but not in normal, untransformed cells. A large number of chemotherapeutics as well as biological agents are being tested for their potential to sensitise resistant tumour cells to TRAIL as a means to broaden the range of tumours treatable with TRAIL. However, because of the incomplete understanding of the mechanism(s) underlying TRAIL resistance in non-malignant cells, it is unpredictable whether the effect of these sensitisers will be restricted to tumour cells or they would also sensitise non-transformed cells causing unwanted toxicity. In this study, we carried out a systematic analysis of the mechanisms driving TRAIL resistance in non-transformed cells. We found that cellular FLICE-like inhibitory protein, anti-apoptotic B-cell lymphoma 2 proteins, and X-linked inhibitor of apoptosis protein were independently able to provide resistance to TRAIL. Deficiency of only one of these proteins was not sufficient to elicit TRAIL sensitivity, demonstrating that in non-transformed cells multiple pathways control TRAIL resistance and they act in a redundant manner. This is contrary to the resistance mechanisms found in tumour cell types, many of them tend to rely on a single mechanism of resistance. Supporting this notion we found that 76% of TRAIL-resistant cell lines (13 out of 17) expressed only one of the above-identified anti-apoptotic proteins at a high level (≥1.2-fold higher than the mean expression across all cell lines). Furthermore, inhibition or knockdown of the single overexpressed protein in these tumour cells was sufficient to trigger TRAIL sensitivity. Therefore, the redundancy in resistance pathways in non-transformed cells may offer a safe therapeutic window for TRAIL-based combination therapies where selective sensitisation of the tumour to TRAIL can be achieved by targeting the single non-redundant resistance pathway.Keywords
This publication has 61 references indexed in Scilit:
- Jetset: selecting the optimal microarray probe set to represent a geneBMC Bioinformatics, 2011
- Akt-phosphorylated Mitogen-activated Kinase-activating Death Domain Protein (MADD) Inhibits TRAIL-induced Apoptosis by Blocking Fas-associated Death Domain (FADD) Association with Death Receptor 4Published by Elsevier BV ,2010
- Neutralization of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Reduces Spinal Cord Injury Damage in MiceNeuropsychopharmacology, 2010
- TRAIL receptor signalling and modulation: Are we on the right TRAIL?Cancer Treatment Reviews, 2009
- TNF-related apoptosis-inducing ligand: Signalling of a ‘smart’ moleculeThe International Journal of Biochemistry & Cell Biology, 2009
- Identification of an antiapoptotic protein complex at death receptorsCell Death & Differentiation, 2008
- Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAILNature Medicine, 2007
- Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitorApoptosis, 2005
- TRAIL Causes Cleavage of Bid by Caspase-8 and Loss of Mitochondrial Membrane Potential Resulting in Apoptosis in BJAB CellsBiochemical and Biophysical Research Communications, 1999
- Safety and antitumor activity of recombinant soluble Apo2 ligandJCI Insight, 1999